Seres Therapeutics (MCRB) Tops Q2 EPS by 5c
Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.22), $0.05 better than the analyst estimate of ($0.27).
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.
Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.22), $0.05 better than the analyst estimate of ($0.27).
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.